Navigation Links
Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal
Date:7/1/2011

forced vital capacity (FVC). At day 84, the aggregate mean change from baseline for all patients was 4.5% and 3.5% for relative percent predicted FEV1 and FVC, respectively. Importantly, combined mean improvements in FEV1 and FVC occurred coincident with the greatest mean improvement in total chloride transport and, with the cessation of ataluren treatment, FEV1 and FVC values reverted towards baseline. The study was not powered to detect statistical significance in these outcome measures and observed changes were not statistically significant.

As an additional secondary endpoint, the study evaluated the frequency of CF-related coughing, which is the most common complaint among patients and often interferes with activities of daily living.(3),(4) During the study, quantitative measurements of CF-related coughing were conducted over a 24-hour period after each clinic visit and results showed that ataluren was associated with an aggregate mean reduction in waking cough frequency of 23% for all patients (p=0.006, paired t-test).

Safety results from the study showed that ataluren was generally well tolerated. Most adverse events were mild or moderate and compliance with study drug was greater than 96% for all patients.

The abstract titled "Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis" is available online at: http://erj.ersjournals.com/content/early/2011/01/13/09031936.00120910.abstract?sid=f34afce6-c9f0-4da2-bcb3-708f931ddda2

ABOUT ATALUREN

An investigational new drug discovered by PTC Therapeutics, ataluren (formerly referred to as PTC124®) is a protein restoration therapy designed to enable the formation of a functioning protein in patients with genetic disorders caused by a nonsense mutation. A nonsense mutation is an alteration in the genetic code that prematu
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. PTC Therapeutics Completes Enrollment of Phase 3 Trial of Ataluren in Patients with Cystic Fibrosis
2. PTC Therapeutics Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy
3. Endo Announces Topline Results From Phase 2 Study of Axomadol in Chronic Low Back Pain
4. Phase III Study Shows Once-Daily NVA237 is Superior to Placebo and Similar to Tiotropium in Improving Lung Function in COPD
5. DNA Medicine Institute Awarded Two Phase III SBIR NASA Contracts for Its rHEALTH Sensor
6. Phase I of the Swedish/Issaquah Medical Center Campus to Open in July
7. The Lancet Publishes Data from Protege, MacroGenics Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
8. Morphotek®, Inc. Announces Initiation of Farletuzumab Phase II Study in First-Line Treatment of Non-Small Cell Lung Cancer
9. Palatin Technologies, Inc. Initiates Enrollment in Phase 2b Trial With Bremelanotide in Women With Female Sexual Dysfunction
10. Cardium Announces Plans to Acquire Transdel Pharmaceuticals Phase 3 Topical Analgesic and Cosmeceutical Business Assets
11. Glycotex, Inc. Releases Final Phase II Clinical Trials Results in the Clinicaltrials.gov Database and Announces the Results of the Mechanism of Action Study for its Product Candidate GLYC-101
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2014)... 12, 2014 Sepsis is a life ... worldwide.  Education and awareness are fundamental to improving ... marks Sepsis Awareness Month and September 13 th ... Sepsis Alliance, "Sepsis, the body,s toxic reaction to ... every year, and thousands more are left with ...
(Date:9/11/2014)... , September 11, 2014 /PRNewswire/ ... Markets ( http://www.researchandmarkets.com/research/lqkmlx/radio_frequency ) has announced the ... Identification (RFID) Market in Healthcare (Tags, ... Industry Analysis, Size, Share, Growth, Trends ... their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ...
(Date:9/11/2014)... , Sept. 11, 2014 Array BioPharma Inc. ... focused on the discovery, development and commercialization of ... cancer, today announced the appointment of Victor ... Sandor will be responsible for leading clinical, medical ... portfolio, including binimetinib, a MEK inhibitor in Phase ...
Breaking Medicine Technology:Nanomix Supports Sepsis Awareness 2Global Radio Frequency Identification (RFID) Market in Healthcare (Tags, Readers, Middleware, Printers and Cabinets) - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2020 2Global Radio Frequency Identification (RFID) Market in Healthcare (Tags, Readers, Middleware, Printers and Cabinets) - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2020 3Array BioPharma Appoints Victor Sandor, M.D., As Chief Medical Officer 2Array BioPharma Appoints Victor Sandor, M.D., As Chief Medical Officer 3Array BioPharma Appoints Victor Sandor, M.D., As Chief Medical Officer 4
(Date:9/14/2014)... September 14, 2014 Proper oral care ... from Butte, Mont., found a way to teach children ... patent-pending B LITE toothbrush encourages an effective brushing habit ... full two minutes without overbrushing, eliminating guesswork and promoting ... easy to use, suitable for all children, and producible ...
(Date:9/14/2014)... Top10BestSEOHosting.com always offers truly reliable ... host suppliers carefully, the site has announced that ... the Best WordPress Hosting suppliers in the current ... top web hosting provider, and the company’s reputation ... hosting provider known for its flexible hosting packages, ...
(Date:9/14/2014)... 2014 UWDress.com, is an internationally well-known ... recently announced its new range of cocktail dresses ... more benefits to worldwide ladies, the company is also ... wedding outfits, blue evening gowns, black formal gowns and ... percent off. , The company’s senior spokesman says, ...
(Date:9/13/2014)... 2014 East Vancouver chiropractor from ... chiropractic clinic, has recently published a blog busting ... blog on the topic, Dr Shervin Ranjbar has ... that people have regarding this branch of medicine. ... of a chiropractor and that of a physiotherapist, ...
(Date:9/13/2014)... (HealthDay News) -- Researchers say they,ve tracked specific activity ... hasn,t been clear whether imagination and memory were distinct ... Provo, Utah, decided to explore the issue. "I ... future and imagining myself in the future, and I ... co-author Stefania Ashby said in a university news release. ...
Breaking Medicine News(10 mins):Health News:Top10BestSEOHosting.com: The Best Linux Web Hosting Suppliers Now Unveiled 2Health News:UWDress.com: Elegant Cocktail Dresses Under $100 Now Offered 2Health News:East Vancouver Chiropractor Releases Blog to Bust Myths about Chiropractic Medicine 2Health News:Scientists Watch Imagination at Work in the Brain 2
... Tender Offer Connected with Previously Announced Plans to Separate Medical ... Technology and Funeral Services Businesses, ... ) (the "Company") announced today that it has,commenced a cash ... percent Senior Notes due 2009 (CUSIP No. 431573AD6), of which ...
... 29 Orchid Cellmark Inc.,(Nasdaq: ORCH ), a ... its fourth quarter and full year 2007 financial,results on ... and is,hosting a conference call and webcast to discuss ... Management will discuss financial results for the,fourth quarter and ...
... With the State of,Minnesota facing a $935 million ... to ensure that the health and independence of,the ... "On the one hand, legislators are discussing meaningful ... chronic conditions, and on the,other, we expect the ...
... The Board of,Directors of Schering-Plough Corporation (NYSE: ... for Ian McInnes, Ph.D., to senior vice,president and ... vice,president, Global Supply Chain. The change reflects the ... that now includes operations from,Organon BioSciences N.V., acquired ...
... the disease , , FRIDAY, Feb. 29 (HealthDay News) -- While ... also play a major role in the development of the ... on more than 40,000 twins born in 1958 or earlier, ... risk for chronic bronchitis and that 14 percent of the ...
... Feb. 29 The American people,through the ... and,a consortium of four partners, will assist ... implement HIV/AIDS prevention, malaria and child,survival programs. ... project,will involve district stakeholders, the private sector ...
Cached Medicine News:Health News:Hillenbrand Industries, Inc. Announces 'Any and All' Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009 2Health News:Hillenbrand Industries, Inc. Announces 'Any and All' Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009 3Health News:Hillenbrand Industries, Inc. Announces 'Any and All' Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009 4Health News:Hillenbrand Industries, Inc. Announces 'Any and All' Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009 5Health News:Orchid Cellmark to Announce Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008 2Health News:Schering-Plough Promotes Ian Mcinnes to President of Global Supply Chain 2Health News:Genetic Factors for Smoking Boost Chronic Bronchitis Risk 2Health News:USAID Implements Behavior Change and Social Marketing Program in Rwanda 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: